Journal of Thrombosis and Thrombolysis
-
Publication Venue For
-
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial..
55:211-221.
2023
-
Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation..
54:393-400.
2022
-
Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens..
54:301-308.
2022
-
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes..
53:841-850.
2022
-
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves..
53:697-707.
2022
-
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes..
53:363-371.
2022
-
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage..
53:167-175.
2022
-
International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests..
52:992-998.
2021
-
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies..
52:419-428.
2021
-
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists..
52:272-280.
2021
-
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population..
51:902-904.
2021
-
Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation..
51:260-264.
2021
-
Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans..
51:249-259.
2021
-
Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis..
51:454-465.
2021
-
The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease..
50:969-981.
2020
-
Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study..
50:484-498.
2020
-
National trends in tranexamic acid use in the peripartum period, 2015-2019..
50:746-752.
2020
-
Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy..
50:452-456.
2020
-
Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation..
50:421-429.
2020
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation..
50:20-29.
2020
-
Direct oral anticoagulants: a review on the current role and scope of reversal agents..
49:271-286.
2020
-
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial..
49:214-219.
2020
-
Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease..
48:373-381.
2019
-
International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin..
48:27-34.
2019
-
Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients..
47:505-511.
2019
-
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial..
47:345-352.
2019
-
"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke..
47:192-199.
2019
-
A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use..
47:16-30.
2019
-
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry..
46:435-439.
2018
-
Cangrelor use prior to left ventricular assist device surgery: a case series..
46:131-133.
2018
-
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study..
45:469-476.
2018
-
Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil..
45:578-587.
2018
-
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial..
45:1-8.
2018
-
Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil..
44:544-555.
2017
-
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy..
44:457-465.
2017
-
Central aortic pulse pressure, thrombogenicity and cardiovascular risk..
44:223-233.
2017
-
Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome..
44:145-153.
2017
-
Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery..
43:446-453.
2017
-
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system..
43:437-445.
2017
-
Etiology and complications of thrombocytopenia in hospitalized medical patients..
43:429-436.
2017
-
ST-elevation no myocardial infarction..
43:426-427.
2017
-
Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients..
43:194-202.
2017
-
Thrombocytopenia in hospitalized patients with severe clostridium difficile infection..
43:38-42.
2017
-
Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction..
42:376-385.
2016
-
Erratum to: Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review..
42:312.
2016
-
Association of weight gain with coronary artery disease, inflammation and thrombogenicity..
41:394-403.
2016
-
Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction..
41:365-373.
2016
-
Erratum to: Guidance for the treatment of deep vein thrombosis and pulmonary embolism..
41:548.
2016
-
Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?.
41:279-284.
2016
-
Guidance for the treatment and prevention of obstetric-associated venous thromboembolism..
41:92-128.
2016
-
Guidance for the treatment of deep vein thrombosis and pulmonary embolism..
41:32-67.
2016
-
Sickle cell disease is associated with iron mediated hypercoagulability..
40:182-185.
2015
-
The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial..
40:17-25.
2015
-
Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials..
39:222-227.
2015
-
D-Dimer elevation and adverse outcomes..
39:55-59.
2015
-
ABO blood group influences transfusion and survival after cardiac surgery..
38:402-408.
2014
-
Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review..
38:285-298.
2014
-
Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases..
38:306-313.
2014
-
The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study..
38:275-284.
2014
-
Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide..
38:73-77.
2014
-
The unmet need for philanthropic funding of early career cardiovascular investigators..
37:527-531.
2014
-
Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal..
37:380-391.
2014
-
Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation..
37:331-337.
2014
-
Emerging paradigms in arterial thrombosis..
37:4-11.
2014
-
Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician..
37:234-241.
2014
-
The pharmacology of novel oral anticoagulants..
37:217-233.
2014
-
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy..
36:375-383.
2013
-
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research..
36:527-532.
2013
-
Oral anticoagulants in older adults with atrial fibrillation..
36:403-415.
2013
-
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting..
36:384-393.
2013
-
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation..
36:163-174.
2013
-
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil..
36:115-130.
2013
-
Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention..
35:57-64.
2013
-
The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa..
35:48-56.
2013
-
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention..
34:499-505.
2012
-
Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician..
34:552-561.
2012
-
Coronary embolism and calcified aortic valve: is there a correlation?.
34:425-427.
2012
-
Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain..
34:229-234.
2012
-
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin..
34:114-119.
2012
-
Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase..
34:126-131.
2012
-
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial..
34:106-113.
2012
-
Biomarker science: on a theme of personalized medicine..
34:141-142.
2012
-
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass..
34:56-64.
2012
-
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil..
34:143-163.
2012
-
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials..
34:44-55.
2012
-
To bridge or not to bridge: these are the questions..
34:31-35.
2012
-
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia..
33:287-295.
2012
-
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy..
33:246-257.
2012
-
The zebra in the room..
33:2.
2012
-
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor..
32:183-187.
2011
-
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil..
32:242-266.
2011
-
Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design..
32:21-31.
2011
-
Early-onset obesity and the unwanted promise of thrombosis..
32:125-128.
2011
-
The many faces of the contact pathway and their role in thrombosis..
32:9-20.
2011
-
Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician..
31:514-522.
2011
-
Antiplatelet agents in cardiovascular disease..
31:306-309.
2011
-
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome..
31:146-153.
2011
-
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial..
31:154-164.
2011
-
Prophylaxis for venous thromboembolism: guidelines translated for the clinician..
31:122-132.
2011
-
A clinical cardiology perspective of thrombophilias..
30:378-389.
2010
-
An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS)..
30:263-275.
2010
-
Examining biology and pharmacology-based hypotheses in the PLATO trial..
30:119-120.
2010
-
Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician..
29:516-528.
2010
-
Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil..
29:395-408.
2010
-
Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician..
29:368-377.
2010
-
Apixaban: an emerging oral factor Xa inhibitor..
29:141-146.
2010
-
Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists..
28:513-514.
2009
-
Aldehyde dehydrogenase activity allows reliable EPC enumeration in stored peripheral blood samples..
28:259-265.
2009
-
Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs..
28:366-380.
2009
-
Treatment of venous thromboembolism: guidelines translated for the clinician..
28:270-275.
2009
-
A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation..
28:132-139.
2009
-
Heparin-dependent platelet factor 4 antibodies and the impact of renal function on clinical outcomes: a retrospective study in hospitalized patients..
28:146-150.
2009
-
Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine..
28:1-5.
2009
-
Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil..
28:106-116.
2009
-
Perioperative management of anticoagulation: guidelines translated for the clinician..
28:16-22.
2009
-
Warfarin in vulnerable older adults with atrial fibrillation..
27:461-464.
2009
-
Biomarker science: direction for the scientific community..
27:355-357.
2009
-
Hemostasis and thrombosis in older adults..
27:249-251.
2009
-
Crossreactivity of Human versus Swine Platelet Surface Antigens Is Similar for Glycoproteins Ib and IIIa, but Not for the Glycoprotein IIb/IIIa Complex..
5:37-41.
1998
-
Survival in Acute Myocardial Infarction Induced by Coronary Ligation: Prognostic Relevance of Certain Hemostatic Factors During the Occlusion Phase..
5:29-35.
1998
-
Adjunctive Antiplatelet Therapy in Acute Myocardial Infarction: The Road to Improved Infarct-Related Artery Patency..
4:353-355.
1997
-
Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective..
4:415-423.
1997
-
Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art..
4:431-439.
1997
-
Economics and Quality of Life After Acute Myocardial Infarction: Insights from GUSTO-I..
3:151-155.
1996
-
Identifying Patient Risk: The Basis for Rational Discharge Planning After Acute Myocardial Infarction..
3:107-115.
1996
-
Succesful Identification and Management of High-Risk Patients with Acute Myocardial Infarction..
3:271-278.
1996
-
Effects of a Novel Leumedin NPC 15669 on Myocardial Stunning and Preconditioned Infarction Size in Swine..
1:163-170.
1995
-
Key References: Antiplatelet Therapy as an Adjunct to Thrombolysis and Coronary Angioplasty..
1:213-216.
1995
-
NPC 15669, an Antiinflammatory Leucine Derivative, Reduces In Vitro Platelet Aggregability in Both Swine and Human Plasma..
1:171-178.
1995
-
Regional and Systemic Platelet Function Is Altered by Myocardial Ischemia-Reperfusion..
1:187-194.
1995